1,734
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Andrographolide engineered gold nanoparticle to overcome drug resistant visceral leishmaniasis

, , , , , & show all
Pages 751-762 | Received 13 Sep 2017, Accepted 29 Jan 2018, Published online: 08 Feb 2018

Figures & data

Figure 1. (A) UV-Vis spectra of AGAunps using different molar ratio of HAuCl4: AG (a) 1:1, (b) 1:1.1, (c) 1:1.2, (d) 1:1.4, (e) 1:1.6, (f) 1:1.8. (B) UV-Vis spectra as a function of reaction time for the reaction of Au and AG at (a) 10 min, (b) 20 min, (c) 25 min, (d) 30 min, (e) 40 min and (f) 50 min.

Figure 1. (A) UV-Vis spectra of AGAunps using different molar ratio of HAuCl4: AG (a) 1:1, (b) 1:1.1, (c) 1:1.2, (d) 1:1.4, (e) 1:1.6, (f) 1:1.8. (B) UV-Vis spectra as a function of reaction time for the reaction of Au and AG at (a) 10 min, (b) 20 min, (c) 25 min, (d) 30 min, (e) 40 min and (f) 50 min.

Figure 2. (A) Particle size, (B) Correlogram, (C) Zeta potential and (D) Phase plot of AGAunp.

Figure 2. (A) Particle size, (B) Correlogram, (C) Zeta potential and (D) Phase plot of AGAunp.

Figure 3. (A) TEM micrograph of AGAunp’s, (B) Histogram of AGAunp size distribution, (C) High resolution TEM micrograph of single AGAunp and (D) AGAunp SAED pattern.

Figure 3. (A) TEM micrograph of AGAunp’s, (B) Histogram of AGAunp size distribution, (C) High resolution TEM micrograph of single AGAunp and (D) AGAunp SAED pattern.

Figure 4. AGAunp EDAX spectrum.

Figure 4. AGAunp EDAX spectrum.

Figure 5. AGAunp AFM scan.

Figure 5. AGAunp AFM scan.

Figure 6. AGAunp XRD spectrum.

Figure 6. AGAunp XRD spectrum.

Figure 7. FTIR overlay of (A) AG and (B) AGAunp.

Figure 7. FTIR overlay of (A) AG and (B) AGAunp.

Figure 8. AG/AGAunp/Standard Antileishmanial drugs sensitivity profile against axenic amastigotes for Leishmania donovani and its drug resistant cell lines. WT (Wild Type), SSG (Sodium stibogluconate resistant) and PMM (paromomycin resistant) cell lines. IC50 (μM) values were determined as mean ± SD (n = 4). *p < .05 significant difference compared with SSG.

Figure 8. AG/AGAunp/Standard Antileishmanial drugs sensitivity profile against axenic amastigotes for Leishmania donovani and its drug resistant cell lines. WT (Wild Type), SSG (Sodium stibogluconate resistant) and PMM (paromomycin resistant) cell lines. IC50 (μM) values were determined as mean ± SD (n = 4). *p < .05 significant difference compared with SSG.

Figure 9. AG/AGAunp/Standard Antileishmanial drugs sensitivity profile against intracellular amastigotes for Leishmania donovani and its drug resistant cell lines. WT (Wild Type), SSG (Sodium stibogluconate resistant) and PMM (paromomycin resistant) cell lines. IC50 (μM) values were determined as mean ± SD (n = 4). *p < .05 significant difference compared with SSG. £p < .5 no significant difference compared with SSG.

Figure 9. AG/AGAunp/Standard Antileishmanial drugs sensitivity profile against intracellular amastigotes for Leishmania donovani and its drug resistant cell lines. WT (Wild Type), SSG (Sodium stibogluconate resistant) and PMM (paromomycin resistant) cell lines. IC50 (μM) values were determined as mean ± SD (n = 4). *p < .05 significant difference compared with SSG. £p < .5 no significant difference compared with SSG.

Table 1. Resistance index (RI), selectivity index (SI) and cytotoxicity of AG/AGAunp/Standard antileishmanial drugs against axenic and intracellular amastigotes for Leishmania donovani and its drug resistant cell linesTable Footnotea.

Figure 10. Macrophage uptake of AGAunp in TEM observed at different time intervals. (A) Macrophages with no AGAunp exposure, (B) after 15 min of AGAunp exposure, (C) after 1 h of AGAunp exposure, (D) after 2 h of AGAunp exposure.

Figure 10. Macrophage uptake of AGAunp in TEM observed at different time intervals. (A) Macrophages with no AGAunp exposure, (B) after 15 min of AGAunp exposure, (C) after 1 h of AGAunp exposure, (D) after 2 h of AGAunp exposure.
Supplemental material

Das_et.al_Supplemental_Material.zip

Download Zip (1 MB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.